Protein Sciences Responds to Emergent BioSolutio...(cation (BLA) with theUS Food and Drug Ad...)

Date:7/10/2008

cation (BLA) with the US Food and Drug Administration (FDA) and PSC's proposal for significant federal funding related to development work for a vaccine to respond to a flu pandemic. Despite this knowledge, EBS provided PSC with the bare minimum of funding and almost always provided less than 60% of each of PSC's funding requests. EBS has only loaned PSC a total of $10,000,000 and has made no loans to PSC since June 16, 2008. In order to assert additional financial pressure on PSC, almost immediately prior to a scheduled meeting of PSC's shareholders to vote on the transaction, EBS alleged that PSC had defaulted under the loan. This allegation of default was made after EBS had learned that PSC's shareholders were unlikely to approve the proposed transaction. While PSC disputes the existence of such loan default, PSC nevertheless cured such alleged default within the allowed time period and in the exact way that EBS had told PSC that it could cure the alleged default.

Because one of the conditions to closing of the transaction was the approval by PSC shareholders, PSC notified its shareholders of the proposed transaction and scheduled a shareholders' meeting to vote on the transaction and other related matters. So that PSC's shareholders could make an informed decision when they voted, PSC issued a Proxy Statement that made a full and fair disclosure of the material facts related to the proposed transaction and the status of PSC's business. The Proxy Statement included information about two very material items: the status of PSC's BLA and its pending request for significant federal funding. EBS was well aware of the status of these items and knew that PSC had already received, and might receive additional, positive material information about either or both of these items after the Proxy Statement was issued and pressed PSC to include in the Proxy Statement additional negative and potentially misleading information about these items. During the proxy process, P
'/>"/>

SOURCE Protein Sciences Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Enhanced Protein Tomography(TM) Method for Rapid Epitope Determination
2. Large-scale community protein annotation -- WikiProteins
3. The Protein Tomography(TM) Award Now Published on Sidecs Homepage
4. CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
5. Sidec Announces the First Protein Tomography(TM) Award at Sidecs Executive Forum at PEGS
6. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
7. Olympus FluoroPoint(TM) System Provides High-Sensitivity Single Molecule and Protein Interaction Analysis for Screening and Research
8. Marteks lifesDHA(TM) Now Available in Protein-free Powder
9. Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
10. Immune system protein starves staph bacteria
11. Decision Biomarkers Launches System for Faster, Easier Quantification of Protein Biomarkers